证券代码：603387 证券简称：基蛋生物 公告编号：2025-007 基蛋生物科技股份有限公司 2024年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：每10股派发现金红利0.9元（含税）。 1、公司拟向全体股东每 10 股派发现金红利 0.9 元（含税）。截至 2024 年 4 月 28 日，公司总股本 507,153,517 股，以此计算合计拟派发现金红利 45,643,816.53 元（含税）。本年度公司现金分红（包括中期已分配的现金红利） 总额 91,287,633.06 元，占本年度归属于上市公司股东净利润的比例为 40.82%。 2、如在本公告披露之日起至实施权益分派股权登记日期间，因可转债转股/ 回购股份/股权激励授予股份回购注销/重大资产重组股份回购注销等致使公司 总股本发生变动的，公司拟维持分配总额不变，相应调整每股分配比例。如后续 总股本发生变化，将另行公告具体调整情况。 本次利润分配方案尚需提交股东大会审议。 本次利润分配以实施权益分派股权登记日 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-016 基蛋生物科技股份有限公司 关于会计差错更正的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 基蛋生物科技股份有限公司（以下简称"基蛋生物"或"公司"）本次更 正内容为追溯调整 2024 年第三季度报告。 本次调整对 2024 年第三季度报告资产总额、所有者权益、归属于母公司 所有者权益、营业收入、净利润、归属于母公司净利润的影响金额具体如下： 单位：元 币种：人民币 | 项目 | 调整金额 | 调整比例 | | --- | --- | --- | | 资产总额 | -95,448,644.93 | -2.43% | | 所有者权益 | -88,173,974.70 | -3.19% | | 其中：归属于母公司所有者权益 | -26,865,709.49 | -1.03% | | 营业收入 | - | - | | 净利润 | -26,815,395.64 | -12.85% | | 其中：归属于母公司净利润 | -26,865,70 ...

Financial Performance - The company's operating revenue for the third quarter was ¥262,156,808.27, a decrease of 11.91% compared to the same period last year[4] - Net profit attributable to shareholders was ¥28,609,951.22, down 52.59% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥18,988,078.64, reflecting a decline of 65.47% compared to the previous year[4] - In the first three quarters of 2024, the company achieved operating revenue of CNY 880 million, a decrease of 12.10% year-on-year[15] - The net profit attributable to shareholders was CNY 175 million, down 23.42% compared to the same period last year[15] - Total operating revenue for the first three quarters of 2024 was ¥879,824,587.76, a decrease of 12.1% compared to ¥1,000,961,989.28 in the same period of 2023[23] - Net profit for the first three quarters of 2024 was ¥181,904,536.85, a decline of 22.2% from ¥233,662,791.59 in the previous year[24] - Total comprehensive income for the period was CNY 189,620,691.30, a decrease from CNY 234,143,463.91 in the previous year[25] Earnings and Shareholder Returns - Basic and diluted earnings per share were both ¥0.06, a decrease of 50.00% compared to the same period last year[4] - Basic and diluted earnings per share decreased to CNY 0.35 from CNY 0.45 year-over-year[25] - The weighted average return on equity decreased to 1.10%, down 1.32 percentage points year-on-year[4] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date was ¥249,907,045.22, an increase of 70.58%[4] - The cash and cash equivalents as of September 30, 2024, were CNY 536.59 million, up from CNY 484.33 million at the end of 2023[18] - The company's cash and cash equivalents decreased to ¥1,930,829,694.44 from ¥2,151,184,140.66 year-over-year[20] - Net cash flow from operating activities increased to CNY 249,907,045.22, compared to CNY 146,507,664.68 in the same period last year, representing a growth of 70.5%[28] - Cash inflow from operating activities totaled CNY 1,125,151,015.42, down from CNY 1,268,627,997.86, a decline of 11.3%[27] - Cash outflow from operating activities decreased to CNY 875,243,970.20 from CNY 1,122,120,333.18, a reduction of 22.0%[28] - Net cash flow from investing activities was negative at CNY -139,612,486.27, an improvement from CNY -349,098,239.79 in the previous year[28] - Cash flow from financing activities resulted in a net outflow of CNY -53,954,549.19, compared to CNY -38,940,372.59 last year[28] - The ending cash and cash equivalents balance increased to CNY 536,086,628.64 from CNY 407,471,086.12 year-over-year[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,839,310,398.65, an increase of 4.40% from the end of the previous year[5] - Total liabilities increased to ¥1,161,681,548.46, compared to ¥1,030,379,608.82 in the previous year[20] - The total owner's equity decreased slightly to ¥2,677,628,850.19 from ¥2,741,246,444.12 year-over-year[21] - The company reported a significant increase in long-term equity investments, rising to ¥122,870,201.52 from ¥50,873,981.61[20] Operational Highlights - The core product, Getein1600, had over 400 units installed in the first three quarters of 2024[15] - The sales revenue from the chemical luminescence line reached CNY 196 million, an increase of 38.43% year-on-year[15] - The overseas revenue from conventional products was CNY 84.99 million, a year-on-year increase of 20.31%[16] - The company installed over 710 units of the small luminescence product MAGICL6000 and MAGICL6000i in various hospitals[15] - The company has installed over 70 units of the Metis6000 fully automated biochemical immunoassay line since its launch[15] Non-Recurring Items - The company recognized government subsidies amounting to ¥6,537,901.80 during the reporting period, contributing positively to the financial results[8] - Non-recurring gains and losses totaled ¥9,621,913.14 for the current period, with a significant portion attributed to government subsidies and other income[9] Changes in Consolidation - The company has decided to no longer consolidate Wuhan Jingchuan Diagnostic Technology Co., Ltd. into its financial statements starting July 1, 2024[16]

Financial Performance - The company's operating revenue for 2024 was CNY 1,164,798,937.40, a decrease of 14.93% compared to CNY 1,369,162,256.52 in 2023[22]. - Net profit attributable to shareholders for 2024 was CNY 223,636,488.43, down 20.06% from CNY 279,771,914.08 in 2023[22]. - The basic earnings per share for 2024 was CNY 0.44, reflecting a decline of 20.00% from CNY 0.55 in 2023[23]. - The cash flow from operating activities increased by 26.94% to CNY 422,998,055.82 in 2024, compared to CNY 333,220,661.81 in 2023[24]. - The company's total assets at the end of 2024 were CNY 3,707,374,587.49, a decrease of 1.70% from CNY 3,771,626,052.94 at the end of 2023[22]. - The weighted average return on equity for 2024 was 8.64%, down from 11.17% in 2023, a decrease of 2.53 percentage points[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 202,042,109.65, a decrease of 16.33% from CNY 241,487,200.13 in 2023[22]. - The company reported a loss of CNY 8,087,939.59 from the disposal of non-current assets in 2024[29]. - The total cash dividends distributed during the reporting period amounted to RMB 91,287,633.06, representing 40.82% of the net profit attributable to shareholders of the listed company[6]. - The company achieved total revenue of CNY 1,164,798,937.40, a year-on-year decrease of 14.93%[79]. - The company's net profit attributable to shareholders was CNY 22,363.65 million, down 20.06% year-on-year[79]. Research and Development - The company invested 207 million RMB in R&D in 2024, focusing on chemiluminescence instruments, line systems, and core raw materials, resulting in 373 new patent authorizations[41]. - The company is focusing on R&D investments in molecular diagnostic systems and smart laboratories, integrating AI-assisted diagnostic technology with hardware[72]. - The company plans to continue increasing investment in R&D projects to enhance product performance and reduce production costs[43]. - The company has 497 R&D personnel, accounting for 25.53% of the total workforce[96]. - The company emphasizes continuous R&D innovation as a core driver, enhancing comprehensive innovation capabilities to expand terminal coverage in the clinical diagnostic market[70]. Product Development and Innovation - The company launched the fully automated biochemical analyzer CM800 with a throughput of 800 tests per hour, featuring 137 sample positions and 114 reagent positions[60]. - The Metis6000 fully automated biochemical immunoassay line was installed nearly 90 times in 2024, with a total of about 140 installations since its launch, 70% of which were in secondary and lower-level hospitals[36]. - The company has established eight major technology platforms, including POCT, chemiluminescence, biochemical testing, and molecular testing, expanding from low-throughput to high-throughput automated systems[57]. - The company has transitioned from a single POCT product line to a diverse product range, including chemiluminescence and biochemical products, and is expanding into both tiered hospitals and overseas markets[57]. - The company launched the GN7120 fully automatic nucleic acid amplification analyzer, enhancing its product matrix for small and medium hospitals[74]. Market Presence and Expansion - The company has expanded its overseas market presence to cover 130 countries and regions, establishing good cooperation with local distributors and healthcare institutions[64]. - The company plans to expand its overseas market presence, particularly promoting its small luminescence products MAGICL6000 and MAGICL6000i across Europe, Africa, Asia, and Latin America[116]. - The company has established over 2,000 product import licenses in 66 countries as of December 31, 2024, enhancing its international market presence[45]. - The overseas revenue from conventional products reached 137 million RMB, representing a year-on-year growth of 4.53%[44]. - The company has installed nearly 40 units of the CM-400 and approximately 70 units of the MAGICL6000 and MAGICL6000i in overseas markets, indicating strong growth potential[45]. Governance and Compliance - The company has established an independent financial department with a complete accounting system, ensuring financial independence[129]. - The company maintains independent operations with no shared bank accounts with controlling shareholders[130]. - The company has a complete and independent asset structure, with no instances of fund or asset occupation by controlling shareholders[128]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[127]. - The company has implemented internal control systems to ensure effective management of subsidiaries and mitigate operational risks[167]. Environmental and Social Responsibility - The company invested 512,300 RMB in environmental protection during the reporting period[172]. - The company ensures that wastewater meets the required standards before being discharged, with regular monitoring of water quality parameters[174]. - The company has implemented measures to control noise pollution, ensuring compliance with relevant noise emission standards[176]. - The company has established a hazardous waste storage facility that meets regulatory requirements and has signed agreements with qualified disposal companies for waste management[176]. - Total donations amounted to 724,000 CNY, with 668,200 CNY in cash contributions[179]. Shareholder Relations and Dividends - The company has committed to a three-year shareholder return plan for 2023-2025, which was approved in the extraordinary shareholder meeting[131]. - The total cash dividend amount for the current period is CNY 91,287,633.06, which represents 40.82% of the net profit attributable to ordinary shareholders[163]. - The company plans to distribute dividends in cash, stock, or a combination of both, with a minimum cash distribution of 10% of the distributable profit for the year if there are no major investment plans or cash expenditures[157]. - The cash dividend distribution ratio is set at a minimum of 80% for mature companies without major expenditures, 40% for mature companies with major expenditures, and 20% for growth-stage companies with major expenditures[158]. - Over the last three accounting years, the cumulative cash dividend amount is CNY 344,864,391.56, with an average annual net profit of CNY 334,106,127.64, resulting in a cash dividend ratio of 103.22%[165].

Financial Performance - The company's operating revenue for Q1 2025 was ¥244,148,446.89, a decrease of 24.08% compared to ¥321,582,715.19 in the same period last year[4] - Net profit attributable to shareholders was ¥64,307,429.35, down 25.24% from ¥86,013,453.60 year-on-year[4] - The basic earnings per share decreased by 23.53% to ¥0.13 from ¥0.17 in the previous year[4] - Net profit for Q1 2025 was ¥62,303,411.24, a decline of 28.8% from ¥87,436,875.95 in Q1 2024[19] - Earnings per share for Q1 2025 was ¥0.13, compared to ¥0.17 in Q1 2024[20] Cash Flow - The net cash flow from operating activities was ¥48,853,750.34, reflecting a decline of 27.21% compared to ¥67,114,506.07 in the same period last year[4] - Cash inflow from operating activities in Q1 2025 was ¥268,090,284.53, down 30.5% from ¥385,853,460.11 in Q1 2024[22] - Cash paid for purchasing goods and services in Q1 2025 was ¥34,212,792.59, a decrease of 64.6% from ¥96,495,187.57 in Q1 2024[22] - Net cash flow from operating activities was $48.85 million, down from $67.11 million, representing a decrease of approximately 27.3%[23] - The total cash and cash equivalents at the end of the period decreased to $274.59 million from $417.29 million, a decline of about 34.2%[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,722,968,542.60, a slight increase of 0.42% from ¥3,707,374,587.49 at the end of the previous year[5] - Total liabilities as of the end of the reporting period were ¥945,912,792.10, down from ¥986,419,351.12 at the end of the previous period[17] - Total equity increased to ¥2,777,055,750.50 from ¥2,720,955,236.37 in the previous period[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,747[9] - The largest shareholder, Su Enben, holds 39.77% of the shares, totaling 201,670,295 shares[9] - Shareholders' equity attributable to shareholders increased by 2.50% to ¥2,684,361,465.12 from ¥2,618,960,854.01 at the end of the previous year[5] Operational Highlights - The company installed over 110 units of the MAGICL6000 and nearly 100 units of the MAGICL6000i in Q1 2025, contributing to growth in the chemiluminescence segment[12] - The Metis6000 fully automated immunoassay production line saw nearly 20 units installed in Q1 2025, with expectations for further growth as market coverage expands[12] - The GN7000/GN7120 fully automated nucleic acid amplification analyzers had over 30 units installed in Q1 2025, with over 70% of installations in secondary and higher-level hospitals[12] Cost Management - The company is focusing on enhancing cost control and improving operational efficiency across its business segments[11] - Total operating costs for Q1 2025 were ¥168,580,188.57, down 23.6% from ¥220,695,492.33 in Q1 2024[18] Investment Activities - Cash inflow from investment activities totaled $150.08 million, compared to $80.93 million, an increase of about 85.5%[23] - Cash outflow from investment activities was $294.03 million, up from $181.35 million, indicating a rise of approximately 62.1%[23] - The net cash flow from investment activities was negative at -$143.95 million, worsening from -$100.42 million[23] Financial Adjustments - The company reported a financial expense of -¥5,922,203.74 in Q1 2025, an improvement from -¥7,500,129.58 in Q1 2024[19] - The company recorded a fair value gain of ¥3,089,177.27 in Q1 2025, compared to a gain of ¥1,342,865.38 in Q1 2024[19] - The impact of exchange rate changes on cash and cash equivalents was a negative $85,746.95, contrasting with a positive impact of $410,246.62 previously[23] Future Outlook - The company aims to expand its market presence while leveraging its R&D capabilities in the IVD product line[11] - The company will not apply new accounting standards starting from 2025[24]

基蛋生物（603387）公告，2025年第一季度营收为2.44亿元，同比下降24.08%；净利润为6430.74万 元，同比下降25.24%。 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-004 基蛋生物科技股份有限公司 关于公司涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否会对上市公司损益产生影响：本次诉讼判决为一审判决，目前尚未 生效，当事人可以在规定期限内提起上诉，该案件最终判决结果存在不确定性， 目前无法判断对公司本期利润或期后利润的影响。公司将根据诉讼进展情况及时 履行信息披露义务，敬请广大投资者理性投资，注意投资风险。 一、本次诉讼的基本情况 基蛋生物科技股份有限公司（以下简称"基蛋生物"或"公司"）作为武汉 景川诊断技术股份有限公司（以下简称"景川诊断"）的控股股东，因股权转让 纠纷事项与景川诊断沟通始终不顺畅，公司无法了解景川诊断经营情况，无法取 得景川诊断相关财务数据，内部审计无法开展，影响了基蛋生物作为上市公司履 行法定信息披露义务。为维护公司作为景川诊断控股股东的法定知情权，公司向 武汉东湖新技术开发区人民法院提起诉讼。 2024 年 12 月，公司收到武汉东湖新技术开发区人民法院送达 ...

哦 根据证券期货投资者适当性管理办法本次电话会议仅服务于华安证券研究所白名单客户本次会议在任何情形下都不构成对会议参加者的投资建议相关人员应自主作出投资决策并自行承担投资风险 华安证券不对任何人因使用会议内容而引致的任何损失承担任何责任未经华安证券事先书面许可任何机构或个人不得以任何形式复制刊载转载转发引用本次会议内容否则由此造成的一切后果及法律责任由该机构或个人承担本公司保留追究其法律责任的权利好的各位 我自愿大家下午好我是华安证券的医药研究员李晨今天在线的还有我们医药行业首席谭国超老师欢迎大家参加我们为期一周的线上特约会本场我们请到的是鸡蛋生物的董事会秘书刘总今天我们会议分两个环节前面的5到10分钟左右 麻烦刘总帮我们在重点介绍一下2023年的一些整体的金融情况后面我们进入问答交流环节下面就先把时间交给刘总刘总您那边可以先简单介绍一下好的 感谢陈总介绍谭国超老师也在线是吧非常感谢咱们华安医药的团队也感谢今天下午餐会的投资者 那么我先把这个公司的一些情况呢做一些更新金兰生物呢这个原来是以这个QCD为主那这两年发展的话也发展成一个NVD平台性的一个公司尤其是二三年那公司的这个主营结构呢也发生了一些比较大的一个 ...

截至2024年三季报，共有50家机构持仓基蛋生物，其中基金50家，合计持股数730.99万股，持股市值 0.60亿元。 4月10日，基蛋生物今日收盘7.92元，上涨2.19%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到15.88倍，总市值40.17亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.15倍，行业中值29.13倍，基蛋生物排 名第32位。 基蛋生物科技股份有限公司主要从事体外诊断试剂与仪器的研发、生产、销售及服务，是国家火炬计划 重点高新技术企业，是国内体外诊断领域（尤其是POCT领域）主要的供应商之一。公司目前主要产品 为自主研发的POCT体外诊断试剂及配套仪器。此外，发行人实现了部分生化乳胶体外诊断试剂产品试 产并开始销售。 最新一期业绩显示，2024年三季报，公司实现营业收入8.80亿元，同比-12.10%；净利润2.02亿元，同 比-11.69%，销售毛利率69.43%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)32基蛋生物15.8814.361.5540.17亿行业平均 46.1548.384.77102.50亿行业中值29.1329.0 ...